In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization
- PMID: 6235909
- PMCID: PMC11039133
- DOI: 10.1007/BF00200047
In vitro elicitation of cytotoxic response against a nonimmunogenic murine tumor by allosensitization
Abstract
The murine lymphoma (thymoma) PIR-2 of C57BL/6 origin, primarily induced in our laboratory by fractionated X-ray irradiation, has been shown to be nonimmunogenic by its failure to immunize syngeneic mice in vivo or to evoke a cytotoxic response in primary mixed lymphocyte-tumor cell cultures (MLTC) in vitro. We were able, however, to demonstrate the existence of anti-PIR-2 cytotoxic cells among allogeneic-primed C57BL/6 responding lymphocytes using the technique of limiting dilution cultures (LDC). The frequency of anti-PIR-2 cytotoxic cells among C57BL/6 lymphocytes sensitized against BALB/c splenocytes in mixed leukocyte culture (MLC) was 1/20 to 1/40, and the cytotoxic activity of positive LDC wells against PIR-2 reached 60% as determined by a 4-h 51Cr-release assay. The frequency of anti-PIR-2 cytotoxic cells could be increased two- to 10-fold (up to 1/4) by removing nylon-wool-adherent cells from the primed cell population and/or by enriching the primed lymphoblast population on a Percoll density gradient. Anti-PIR-2 cytotoxic cells were found to be Thy1+; Lyt1-2+ cells. Clones isolated from the LDC wells manifested strong cytotoxic activity toward PIR-2 cells and the stimulating BALB/c splenocytes but not against other H-2b tumor lines or C57BL/6 splenocytes. We suggest that the procedure of allostimulation in MLC-LDC is an effective in vitro means of generating highly reactive cytotoxic cells against poorly immunogenic neoplasms.
Similar articles
-
Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization.J Exp Med. 1990 Apr 1;171(4):1057-71. doi: 10.1084/jem.171.4.1057. J Exp Med. 1990. PMID: 2139097 Free PMC article.
-
Allosensitization in IL-2-containing limiting dilution cultures generates cytotoxic T lymphocytes (CTL) rather than LAK cells reactive with a syngeneic nonimmunogenic murine tumor.Immunol Lett. 1989 Jan 15;20(1):53-8. doi: 10.1016/0165-2478(89)90068-0. Immunol Lett. 1989. PMID: 2785493
-
Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.J Immunol. 1984 Jun;132(6):3218-25. J Immunol. 1984. PMID: 6202778
-
Methods for amplifying the induction and expression of cytotoxic response in vitro to syngeneic and autologous freshly-isolated solid tumors of mice.Cancer Immunol Immunother. 1984;18(2):126-34. doi: 10.1007/BF00205747. Cancer Immunol Immunother. 1984. PMID: 6239683 Free PMC article.
-
In vitro induction of cell-mediated immunity to murine leukemia cells. II. cytotoxic activity in vitro and tumor-neutralizing capacity in vivo of anti-leukemia cytotoxic lymphocytes generated in macrocultures.J Immunol Methods. 1977;16(1):39-58. doi: 10.1016/0022-1759(77)90038-2. J Immunol Methods. 1977. PMID: 68086
Cited by
-
Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells.Cancer Immunol Immunother. 1986;21(3):199-204. doi: 10.1007/BF00199362. Cancer Immunol Immunother. 1986. PMID: 2938737 Free PMC article.
-
Mouse lymphoblasts lose their immunogenicity and susceptibility to specific cytotoxic T lymphocyte lysis during maintenance in culture.Immunology. 1998 Nov;95(3):409-18. doi: 10.1046/j.1365-2567.1998.00611.x. Immunology. 1998. PMID: 9824505 Free PMC article.
-
Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells.Cancer Immunol Immunother. 1985;20(3):198-204. doi: 10.1007/BF00205576. Cancer Immunol Immunother. 1985. PMID: 3851699 Free PMC article.
-
Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions.Cancer Immunol Immunother. 1988;26(1):74-82. doi: 10.1007/BF00199851. Cancer Immunol Immunother. 1988. PMID: 3257904 Free PMC article.
-
Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type.Cancer Immunol Immunother. 1989;29(1):74-8. doi: 10.1007/BF00199920. Cancer Immunol Immunother. 1989. PMID: 2785003 Free PMC article.
References
-
- Aoki T, Herberman RB, Hartley JW, Liu M, Walling NJ, Nunn M. Surface antigens on transplantable tumor cell-lines producing mouse type C viruses. J Natl Cancer Inst. 1977;58:1065. - PubMed
-
- Bach FH, Leshem B, Kuperman OJ, Bunzendahl H, Alter BJ, Zarling JM. Allosensitization to obtain anti-tumor immunity. In: Fefer A, Goldstein A, editors. The potential role of T cells in cancer therapy. New York: Raven; 1982. p. 7.
-
- Finke JH, Fyfe DA, Del Villano BC, Butler GH, Ponzio NM. Characterization of “foreign” alloantigen-like specificities on a murine lymphoma cell line. Transplant Proc. 1980;12:53. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous